McKesson Corporation · MCK · Next earnings

McKesson Corporation reports Wednesday, Nov 4, 2026

MCK reports after market close with consensus EPS at $10.72 and revenue at $109.88B. Last quarter: McKesson Closes FY2026 With 18% EPS Growth, Reaffirms FY27 Outlook

Reports After market close45 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $10.72 Calendar consensus
Consensus revenue $109.88B Calendar consensus
Report date Nov 4, 2026 Wednesday, date estimated
Session After market close 45 days away

Where MCK left off: FY2026 Q4

Full report

McKesson Closes FY2026 With 18% EPS Growth, Reaffirms FY27 Outlook

EPS surprise +1.1% Reported $11.69 vs $11.56
Revenue surprise -5.0% Reported $96.30B vs $101.35B
Stock move -2.5% Event window
Subsequent drift +4.2% Up to 20 sessions

Management maintained FY27 EPS guidance of $43.80-$44.60, implying 12-14% year-over-year growth. This follows the prior quarter's raised full-year FY26 EPS guidance to $38.80-$39.20. The guidance sentiment shifted from 'raised' in Q3 to 'maintained' in Q4, suggesting management sees the current trajectory as on track rather than accelerating further.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Inflation Reduction Act pricing changes affecting branded pharmaceutical revenue.
  • Weather-related supply chain disruptions impacting distribution operations.
  • Margin pressure from biosimilar adoption and lower average selling prices.
  • Regulatory approvals required for the Medical-Surgical Solutions carve-out and Apollo investment.
  • Continued price declines for branded drugs in the North American Pharmaceutical segment.

Questions analysts left open

  • RxTS segment growth rate and 3PL contribution
  • GLP-1 growth expectations within prior-authorization business
  • Organic versus inorganic contribution to oncology and multispecialty guidance
  • Free cash flow outlook decline and capital allocation priorities
  • North American Pharmaceutical utilization trends

Ask FN2 about MCK next report

Transcript, numbers and history already loaded
What should I watch for in MCK's next earnings report?How did MCK guide last quarter, and is consensus above or below that?Give me the bull and bear case going into MCK earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the MCK recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent MCK quarters

All MCK earnings
-2.5%FY2026 Q4

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q4

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.